webinars.endpts.com Open in urlscan Pro
54.185.102.17  Public Scan

Form analysis
0 forms found in the DOM

Text Content

 * Endpoints News
 * watch now

WEBINAR RECORDING AVAILABLE - WATCH ON DEMAND


EVOLUTION OF CELL & GENE THERAPY IN CHINA: THE CASE FOR UNIVERSAL CAR-T

China now represents 60% of clinical development in CAR-T therapy development
globally: what have we learned to date and where are future opportunities?

IN THIS WEBINAR YOU WILL LEARN ABOUT:

 * The current landscape of biotech & development of CAR-T therapy clinical
   development in China
 * CAR-T clinical development in China: key areas of focus
 * Potential opportunities related to universal CAR-T cell therapy development

SPONSORED BY
SHARE ON

watch now
Watch the webinar on demand
watch now


JIE CHEN

CHIEF MEDICAL OFFICER, BIOHENG

Dr. Chen has over 15 years of experience as an oncology clinician and over 21
years of experience in the industry. Prior to joining Bioheng, Dr. Chen served
as the Head of Medical Affairs and the Vice President at Takeda China, where he
was responsible for supporting the launch and product cycle management of
innovative products such as Adcetris ®, Entyvio ®, Vocinti ®, Takhzyro ®,
Firazyr ®, Edarbi ® and myPKfit®. Additionally, he held executive positions in
Medical Affairs at Bristol-Myers Squibb (BMS), Pfizer, and Sunway biotech.

He was a major contributor to the first NMPA approval for a lysing virus and was
responsible for the pre-marketing and launch of several oncology products such
as Sunitinib, Crizotinib, and Nabumetinib in China.

Dr. Chen holds an MD degree from the Army Medical University and has
postdoctoral experience from Fudan University. He is currently a member of the
CSCO Expert Committee on Tumor Bio-marker, the CSCO Expert Committee on Tumor
Immunotherapy (IO), an Honorary Member of CACA Professional Committee on
Oncology Drug Research, and the CSCO Expert Committee on Translational Medicine.


WEILI ZHAO

VICE PRESIDENT, RUIJIN HOSPITAL

Weili Zhao, M.D., PhD, is a Professor of Hematology and the First Deputy
Director of the Shanghai Institute of Hematology, and the Vice President and
Associate Chief Physician of the Department of Hematology, at the Shanghai
Ruijin Hospital. She is the doctoral supervisor of both Shanghai Jiao Tong
University and the University Paris VII. Dr. Zhao is a foreign member of
American Society of Hematology, the Vice President of the Chinese Association of
Hematology, Secretary General of the Chinese Society of Experimental Hematology,
and a member of the editorial committee of Pathobiology, Biomarker Research, at
the Chinese Journal of Hematology, Chinese Journal of Leukemia & Lymphoma, and
the Clinical Hematology Journal.

She mainly focuses on the clinical and basic research of hematological
malignancies, especially the molecular mechanism and targeted therapy of
malignant lymphoma. She innovatively proposed the molecular pathways of
apoptosis, angiogenesis and cell differentiation involved in lymphoma
progression and the availability of targeted agents for treatment.

Dr. Zhao has been awarded the National Award for Science and Technology Progress
and Outstanding Achievement Award of Scientific Research from the National
Ministry of Education and the HUA XIA Award of Medicine and Technology from the
National Ministry of Science and Technology for her research. She is now leading
projects granted by the National High Technology Research and Development
Program of China, the National Natural Science Foundation of China and several
other events on a provincial level. She has been honored New Century Excellent
Talents in University by the State Ministry of Education. She has been honored
as a Rising Star by the Program for New Century Excellent Talents in University
by the State Ministry of Education, and Shu Gang Scholar by the Shanghai
Municipal Educational Committee. She has published over 70 articles including
those on leading hematology journals like cancer cell, nature genetics, blood,
molecular cancer, and more, with total impact factors over 500.


VIVIAN GU

HEAD OF CDR, CHINA CMO, NOVOTECH PPC

Dr. Gu has a degree in Clinical Medicine from Fudan University, also previously
known as Shanghai Medical University. With 8 years of physician experience in
the internal medicine department in tertiary care hospital, Dr. Gu continues to
contribute to her field intensively.

Dr. Gu has substantial experience with over 20 years of working at companies
such as BI, AZ, BMS in the clinical research department. Dr. Gu has also worked
as the head of CO for MNC of various industries for 16 years. Prior to joining
PPC, she was a Senior VP of a leading China biotech company and carries rich
experience after managing clinical, medical & regulatory affairs. With her
wealth of experience, she has a deep insight into R&D needs and pathways for
China's local biotech.

In addition, Dr. Gu also holds abundant experience across all the therapeutic
areas in the clinical trials industry i.e onco, non-onco, such as Lung cancer,
Liver cancers etc., PD- CLTA4, EGFR-TKI etc.


KAI XUE

ASSOCIATE PROFESSOR, DEPARTMENT OF HEMATOLOGY, RUIJIN HOSPITAL, SHANGHAI CHINA

Dr. Xue gained his master's degree in Hematology from Shanghai Jiao Tong
University and a doctor's degree in Oncology from Fudan University and has 17
years of experience in hematological oncology. He worked at Fudan University
Shanghai Cancer Center from 2009 to 2018, and since 2019, he has worked in
Shanghai Ruijin Hospital. In 2013-2014, he studied at Roswell Park Cancer
Institute as a visiting scholar under the supervision of world-renowned lymphoma
expert Myron Czucuman. Dr. Xue has led two multicenter clinical trials and
participated in more than 40 Chinese/international trials in the field of
hematological oncology.

Dr. Xue is currently a member of the Youth Committee of the Hematological
Oncology Professional Committee, the Chinese Anti-Cancer Association, the Youth
Committee of the Chinese Society of Clinical Oncology (CSCO), the Vice-Chairman
of the Youth Committee,the Hematology Branch of the Shanghai Medical
Association, and a member of the clinical research committee of antitumor drugs
of the Shanghai Anti-Cancer association. He has published over 15 scientific
papers and gave oral presentations at the 54th annual ASH meeting.

MODERATOR


ARSALAN ARIF

FOUNDER & PUBLISHER, ENDPOINTS NEWS

Arsalan Arif is a news media entrepreneur who set out in 2015 to build his
vision of an independent biotech news company at Endpoints News.

close


YOUR SEAT IS RESERVED!


EVOLUTION OF CELL & GENE THERAPY IN CHINA: THE CASE FOR UNIVERSAL CAR-T

1:00 pm - 2:00 pm EDT
17:00 - 18:00 LOCAL TIME

A confirmation email with information on how to join the webinar has been sent
to you.

Before joining, be sure to check system requirements to avoid any connection
issues.

close


REGISTRATION DECLINED


EVOLUTION OF CELL & GENE THERAPY IN CHINA: THE CASE FOR UNIVERSAL CAR-T

The webinar sponsor has requested specific attendance parameters for this
webinar.

We apologize for any inconvenience this may cause and we hope you will join us
for future webinars.